INTRAPERITONEAL METHOTREXATE AND DIPYRIDAMOLE AS SALVAGE TREATMENT FOR ADVANCED OVARIAN CARCINOMA
OBJECTIVES: I. Determine the clinical complete and partial response rate, pathological
complete response rate, disease-free survival, and duration of response produced by
intraperitoneal dipyridamole/methotrexate (DP/MTX) administered as a 7-day continuous
infusion in patients with advanced ovarian carcinoma that is recurrent following or
refractory to cisplatin-based chemotherapy. II. Determine the peritoneal and systemic
toxicity of DP/MTX.
OUTLINE: Nonrandomized study. Single-Agent Chemotherapy with Chemopotentiation.
Methotrexate, MTX, NSC-740; with Dipyridamole, DP, NSC-515776.
PROJECTED ACCRUAL: Up to 40 evaluable patients in each category (prior intraperitoneal vs.
prior intravenous platinum-based chemotherapy) will be studied. If no responses are seen in
the first 20 patients in either category, accrual to that category will cease. An accrual
rate of 15 patients/year is anticipated.
Primary Purpose: Treatment
Rakesh Goel, MD, FRCPC
Ottawa Regional Cancer Centre
United States: Federal Government